Early response to anti-TNF predicts long-term outcomes including sustained remission: An analysis of the BSRBR-RA

TY - JOUR

T1 - Early response to anti-TNF predicts long-term outcomes including sustained remission

T2 - An analysis of the BSRBR-RA

AU - Hamann, Philip D.H.

AU - Pauling, John D.

AU - McHugh, Neil

AU - Hyrich, Kimme

AU - Shaddick, Gavin

N1 - Funding Information: Funding: This work was supported by the British Society for Rheumatology (BSR). The BSR commissioned the BSR Biologics Register in rheumatoid arthritis (BSRBR-RA) as a UK wide national project to investigate the safety of biologic agents in routine medical practice. K.H. is the principal investigator. BSR receives restricted income from UK pharmaceutical companies, including Abbvie, Celltrion, Hospira, MSD, Pfizer, SOBI, Samsung, UCB and Roche. This income finances a wholly separate contract between the BSR and the University of Manchester. The principal investigator and the BSRBR-RA team at the University of Manchester have full academic freedom and are able to work independently of pharmaceutical industry influence. All decisions concerning analyses, interpretation and publication are made autonomously of any industrial contribution. Members of the BSRBR-RA University of Manchester team, BSR trustees, committee members and staff complete an annual declaration in relation to conflicts of interest. All relevant information regarding serious adverse events outlined in the manuscript have been reported to the appropriate pharmaceutical company as per the contractual agreements/standard operating procedures. Funding Information: The authors acknowledge the enthusiastic collaboration of all consultant rheumatologists and their specialist nurses in the UK in providing the data (visit www.bsrbr. org for a full list of contributors). The authors would like to gratefully acknowledge the support of the National Institute for Health Research, through the Comprehensive Local Research Networks at participating centres. In addition, the authors acknowledge support from the BSR Executive, the members of the BSRBR Registers Committee and the BSRBR Project Team in London for their active role in enabling the register to undertake its tasks. The authors also acknowledge the seminal role of the BSR Clinical Affairs Committee for establishing national biologic guidelines and recommendations for such a register. This work was conducted on behalf of BSR, and P.H. would like to thank BSR for its help and support. Infrastructure, database and statistical support for the BSRBR-RA was also received from the Arthritis Research UK Centre for Epidemiology (Arthritis Research UK Grant ID 21755). P.H.’s research was funded by the BSR through the Clinical Research Fellowship in Musculoskeletal Epidemiology. Publisher Copyright: © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.

PY - 2020/7/1

Y1 - 2020/7/1

KW - biologic therapies

KW - DMARDS

KW - epidemiology

KW - outcome measures

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85075763737&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kez518

DO - 10.1093/rheumatology/kez518

M3 - Article

C2 - 31714580

AN - SCOPUS:85075763737

SN - 1462-0324

VL - 59

SP - 1709

EP - 1714

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

IS - 7

ER -